A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
Status:
Completed
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram
(mg) pimodivir in adult participants with impaired hepatic function compared to adult
participants with normal hepatic function.